Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,780Revenue $M6.5Net Margin (%)-1,898.5Z-Score78.0
Enterprise Value $M3,292EPS $-5.9Operating Margin %-1,899.1F-Score2
P/E(ttm))0Cash Flow Per Share $-1.4Pre-tax Margin (%)-1,897.4Higher ROA y-yN
Price/Book6.510-y EBITDA Growth Rate %0Quick Ratio21.7Cash flow > EarningsY
Price/Sales5165-y EBITDA Growth Rate %0Current Ratio21.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-30.9Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-32.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M33.2ROI % (ttm)-27.3Gross Margin Increase y-yN

Gurus Latest Trades with GEVA

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GEVAGeorge Soros 2013-12-31 Sold Out -0.01%$45.51 - $69.69
($59.17)
$ 102.2973%Sold Out0
GEVAGeorge Soros 2013-09-30 Buy 0.01%$43.26 - $62.55
($49.11)
$ 102.29108%New holding, 17700 sh.17,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GEVA is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


GEVA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOESS CARSTENSVP, CFO 2015-02-17Sell42,297$100.112.07view
BAKER JULIANDirector, 10% Owner 2015-01-07Buy1,000,000$94.198.48view
BAKER FELIXDirector, 10% Owner 2015-01-07Buy1,000,000$94.198.48view
Heberlig ChrisGroup Vice President, Finance 2014-12-29Sell6,100$91.1412.11view
Patel Sanj KPresident & CEO 2014-12-17Sell50,000$88.8515view
BOESS CARSTENSVP, CFO 2014-10-30Sell25,404$80.127.57view
Goldberg Mark AlanEVP, Medical & Reg. Strategy 2014-09-19Sell790$65.2456.62view
Goldberg Mark AlanEVP, Medical & Reg. Strategy 2014-09-17Sell13,579$65.0357.13view
Quinn AnthonyEVP, CMO & Head of R&D 2014-09-02Sell10,000$70.1445.68view
Williams GlenSVP, Technical Operations 2014-06-25Sell700$108.02-5.41view

Press Releases about GEVA :

    Quarterly/Annual Reports about GEVA:

    News about GEVA:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    10-K for Synageva BioPharma Corp. Feb 28 2015
    Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day... Feb 27 2015
    Synageva BioPharma reports 4Q loss Feb 26 2015
    Synageva BioPharma reports 4Q loss Feb 26 2015
    Synageva Biopharma Corp Earnings Call scheduled for 4:30 pm ET today Feb 26 2015
    SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 26 2015
    Synageva BioPharma Reports 2014 Full Year Financial Results Feb 26 2015
    Q4 2014 Synageva Biopharma Corp Earnings Release - After Market Close Feb 26 2015
    Synageva BioPharma To Present At The Cowen and Company Health Care Conference Feb 25 2015
    FDA Accepts BLA Filing For Synageva's Kanuma™ (Sebelipase Alfa); Grants Priority Review And... Feb 23 2015
    Synageva BioPharma To Host 2014 Fourth Quarter And Full Year Financial Results Conference Call On... Feb 19 2015
    Synageva European Patent Issued For Treatment Of LAL Deficiency Feb 18 2015
    Synageva BioPharma Announces Presentations At 11th Annual World Symposium Feb 11 2015
    SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 09 2015
    SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 02 2015
    Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog Jan 28 2015
    Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For... Jan 26 2015
    Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For... Jan 26 2015
    Undercover biotech bets: RARE, AMAG & GEVA Jan 15 2015
    SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 07 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK